Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with or without Tifcemalimab as consolidation after chemoradiotherapy for limited-stage small cell lung cancer
CTR20233182Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tifcemalimab, toripalimab in small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Nov 2023; status: active.
02
Drugs
tifcemalimabtoripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20233182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233182.